Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLRNASDAQ:GLYCOTCMKTS:SPRCYNYSEAMERICAN:SYN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$0.85-5.1%$0.96$0.61▼$18.64$12.74M-0.141.11 million shs616,266 shsGLYCGlycoMimetics$0.21-1.6%$0.23$0.14▼$0.63$13.55M1.76.46 million shs586,195 shsSPRCYSciSparc$4.00-19.0%$4.00$2.75▼$12.25$4.15M-0.0810,035 shs12,500 shsSYNSynthetic Biologics$0.00$0.97▼$4.56$16.16M1.38197,338 shs57,700 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics0.00%-17.96%-23.87%-3.99%-95.43%GLYCGlycoMimetics0.00%-14.13%-19.84%-18.94%-22.62%SPRCYSciSparc0.00%0.00%0.00%0.00%0.00%SYNSynthetic Biologics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLRAllarity Therapeutics0.5333 of 5 stars0.04.00.00.01.60.00.6GLYCGlycoMimetics1.6385 of 5 stars0.04.00.04.62.21.70.0SPRCYSciSparcN/AN/AN/AN/AN/AN/AN/AN/ASYNSynthetic BiologicsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity Therapeutics 0.00N/AN/AN/AGLYCGlycoMimetics 2.33HoldN/AN/ASPRCYSciSparc 0.00N/AN/AN/ASYNSynthetic Biologics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SPRCY, SYN, ALLR, and GLYC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2025GLYCGlycoMimeticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity TherapeuticsN/AN/AN/AN/A($559.39) per shareN/AGLYCGlycoMimetics$10K1,353.24N/AN/A$0.08 per share2.62SPRCYSciSparcN/AN/A$2.65 per share1.51$1.38 per shareN/ASYNSynthetic BiologicsN/AN/AN/AN/A$4.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$11.90MN/A0.00N/AN/AN/A-369.67%-100.06%8/4/2025 (Estimated)GLYCGlycoMimetics-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%8/14/2025 (Estimated)SPRCYSciSparc-$3.48M$14.940.27N/AN/AN/AN/AN/AN/ASYNSynthetic Biologics-$14.27M-$1.21N/AN/AN/AN/A-26.14%-22.74%N/ALatest SPRCY, SYN, ALLR, and GLYC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025GLYCGlycoMimetics-$0.05-$0.04+$0.01-$0.04N/AN/A5/13/2025Q1 2025ALLRAllarity Therapeutics-$8.10-$0.25+$7.85-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/AGLYCGlycoMimeticsN/AN/AN/AN/AN/ASPRCYSciSparcN/AN/AN/AN/AN/ASYNSynthetic BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A2.752.75GLYCGlycoMimeticsN/A1.921.92SPRCYSciSparcN/A11.052.25SYNSynthetic BiologicsN/A4.144.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%GLYCGlycoMimetics75.19%SPRCYSciSparcN/ASYNSynthetic Biologics74.38%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.08%GLYCGlycoMimetics8.70%SPRCYSciSparcN/ASYNSynthetic Biologics2.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics1015.08 million4.43 millionNot OptionableGLYCGlycoMimetics5064.53 million58.90 millionOptionableSPRCYSciSparc21.04 millionN/ANot OptionableSYNSynthetic Biologics1615.84 million15.50 millionNot OptionableSPRCY, SYN, ALLR, and GLYC HeadlinesRecent News About These CompaniesBioNext: Generics to biologics, India’s moment to leadMay 26, 2025 | msn.comBiologics, Targeted Therapies Best for Acute PsA DactylitisMay 21, 2025 | medscape.comInfection Patterns Matter in Selection of Advanced Therapies for Inflammatory ArthritisMay 16, 2025 | medscape.comAnsa Biotechnologies Rolls Out Early Access Program for Long, Complex Synthetic DNA OrdersMay 11, 2025 | genengnews.comMaxim Group Downgrades Theriva Biologics (TOVX)May 9, 2025 | msn.comAI and Machine Learning as Transformative BioToolsMay 8, 2025 | genengnews.comCytiva and Asimov collaborate on next generation cell line design and process developmentApril 30, 2025 | pharmiweb.comCytiva and Asimov Collaborate on NextGen Cell Line Design and Process DevelopmentApril 29, 2025 | genengnews.comSynthetic Design emerges with $20M and next-gen ADC platformApril 26, 2025 | bioworld.comSeries A financing at Grove BiopharmaApril 25, 2025 | bioworld.com$30 million helps Grove go after hard-to-treat cancersApril 24, 2025 | thepharmaletter.comSynthetic Design Lab Emerges with $20M to Advance Next-Generation ADCsApril 24, 2025 | finance.yahoo.comUS to Phase Out Many Synthetic Food Dyes, Kennedy and FDA Head SayApril 24, 2025 | usnews.comGrove Biopharma Closes $30 Million Series A Financing to Advance Bionic Biologics™, a New Therapeutic ModalityApril 24, 2025 | finance.yahoo.comPharma startup out of Portal's lab raises $30M for cancer-fighting biologicsApril 24, 2025 | chicagobusiness.comThe Increasing Value Of The Synthetic Biology Market By 2035April 17, 2025 | pharmiweb.comSynthetic control arms: full impact yet to be realisedApril 16, 2025 | msn.comFuture Opportunities In The Synthetic Biology Market Landscape Until 2035April 16, 2025 | pharmiweb.comNewly approved DMARDs can appear less safe due to ‘channeling’ phenomenonApril 8, 2025 | healio.comBiologics Outperform Conventional Therapy in Still’s DiseaseApril 8, 2025 | medscape.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPRCY, SYN, ALLR, and GLYC Company DescriptionsAllarity Therapeutics NASDAQ:ALLR$0.84 -0.05 (-5.06%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.87 +0.02 (+2.60%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.GlycoMimetics NASDAQ:GLYC$0.21 0.00 (-1.64%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.21 +0.00 (+0.14%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.SciSparc OTCMKTS:SPRCYSciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. SciSparc Ltd. has an agreement with Procaps to develop and commercially manufacture SCI-110, as well as CannAmide, a palmitoylethanolamide compound in softgel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to perform a pre-clinical study for the evaluation of SCI-210 drug development program for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv, Israel.Synthetic Biologics NYSEAMERICAN:SYNSynthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
